NYSE American - Delayed Quote USD

NovaBay Pharmaceuticals, Inc. (NBY)

0.0725 -0.0099 (-12.01%)
At close: April 22 at 4:00 PM EDT
0.0720 -0.00 (-0.69%)
Pre-Market: 8:24 AM EDT
Loading Chart for NBY
DELL
  • Previous Close 0.0824
  • Open 0.0833
  • Bid 0.0708 x 2200
  • Ask 0.0719 x 3100
  • Day's Range 0.0650 - 0.0860
  • 52 Week Range 0.0650 - 1.4200
  • Volume 3,954,343
  • Avg. Volume 3,606,291
  • Market Cap (intraday) 2.614M
  • Beta (5Y Monthly) 2.01
  • PE Ratio (TTM) --
  • EPS (TTM) -3.9600
  • Earnings Date May 9, 2024 - May 13, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 2.60

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

novabay.com

24

Full Time Employees

December 31

Fiscal Year Ends

Recent News: NBY

Q4 2023 NovaBay Pharmaceuticals Inc Earnings Call

Performance Overview: NBY

Trailing total returns as of 4/22/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

NBY
63.75%
S&P 500
5.05%

1-Year Return

NBY
95.35%
S&P 500
21.22%

3-Year Return

NBY
99.72%
S&P 500
20.06%

5-Year Return

NBY
99.81%
S&P 500
72.48%

Compare To: NBY

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NBY

Valuation Measures

Annual
As of 4/23/2024
  • Market Cap

    2.61M

  • Enterprise Value

    4.17M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.02

  • Price/Book (mrq)

    1.92

  • Enterprise Value/Revenue

    0.28

  • Enterprise Value/EBITDA

    -0.87

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -65.46%

  • Return on Assets (ttm)

    -24.59%

  • Return on Equity (ttm)

    -139.02%

  • Revenue (ttm)

    14.73M

  • Net Income Avi to Common (ttm)

    -16.7M

  • Diluted EPS (ttm)

    -3.9600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.13M

  • Total Debt/Equity (mrq)

    82.68%

  • Levered Free Cash Flow (ttm)

    -173.88k

Research Analysis: NBY

Analyst Price Targets

2.00
2.60 Average
0.0725 Current
3.20 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Company Insights: NBY

Fair Value

0.0725 Current
 

Dividend Score

0 Low
NBY
Sector Avg.
100 High
 

Hiring Score

0 Low
NBY
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
NBY
Sector Avg.
100 High
 

People Also Watch